ACXP Quote, Financials, Valuation and Earnings

Palatin Technologies has a net margin of -- compared to Acurx Pharmaceuticals, Inc.'s net margin of --. Acurx Pharmaceuticals, Inc.'s return on equity of -358.38% beat Palatin Technologies's return on equity of --.

Acurx Pharmaceuticals, Inc. has a consensus price target of $61.70, signalling upside risk potential of 1672.99%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Acurx Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than Acurx Pharmaceuticals, Inc..

Acurx Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Acurx Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acurx Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Acurx Pharmaceuticals, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Acurx Pharmaceuticals, Inc.'s net income of -$2M is higher than Palatin Technologies's net income of --. Notably, Acurx Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acurx Pharmaceuticals, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Synergy CHC has a net margin of -- compared to Acurx Pharmaceuticals, Inc.'s net margin of --. Acurx Pharmaceuticals, Inc.'s return on equity of -358.38% beat Synergy CHC's return on equity of --.

Acurx Pharmaceuticals, Inc. has a consensus price target of $61.70, signalling upside risk potential of 1672.99%. On the other hand Synergy CHC has an analysts' consensus of -- which suggests that it could fall by --. Given that Acurx Pharmaceuticals, Inc. has higher upside potential than Synergy CHC, analysts believe Acurx Pharmaceuticals, Inc. is more attractive than Synergy CHC.

Acurx Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Synergy CHC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Acurx Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Synergy CHC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acurx Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Synergy CHC pays out -- of its earnings as a dividend.

Acurx Pharmaceuticals, Inc. quarterly revenues are --, which are larger than Synergy CHC quarterly revenues of --. Acurx Pharmaceuticals, Inc.'s net income of -$2M is higher than Synergy CHC's net income of --. Notably, Acurx Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Synergy CHC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acurx Pharmaceuticals, Inc. is -- versus -- for Synergy CHC. Usually stocks with elevated PS ratios are considered overvalued.

Sharps Technology, Inc. has a net margin of -- compared to Acurx Pharmaceuticals, Inc.'s net margin of -4601.72%. Acurx Pharmaceuticals, Inc.'s return on equity of -358.38% beat Sharps Technology, Inc.'s return on equity of -111.89%.

Acurx Pharmaceuticals, Inc. has a consensus price target of $61.70, signalling upside risk potential of 1672.99%. On the other hand Sharps Technology, Inc. has an analysts' consensus of $22.00 which suggests that it could grow by 645.76%. Given that Acurx Pharmaceuticals, Inc. has higher upside potential than Sharps Technology, Inc., analysts believe Acurx Pharmaceuticals, Inc. is more attractive than Sharps Technology, Inc..

Acurx Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sharps Technology, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Acurx Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sharps Technology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acurx Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Sharps Technology, Inc. pays out -- of its earnings as a dividend.

Acurx Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Sharps Technology, Inc. quarterly revenues of $2.3M. Acurx Pharmaceuticals, Inc.'s net income of -$2M is higher than Sharps Technology, Inc.'s net income of -$105.3M. Notably, Acurx Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Sharps Technology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acurx Pharmaceuticals, Inc. is -- versus 7.46x for Sharps Technology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -- compared to Acurx Pharmaceuticals, Inc.'s net margin of --. Acurx Pharmaceuticals, Inc.'s return on equity of -358.38% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Acurx Pharmaceuticals, Inc. has a consensus price target of $61.70, signalling upside risk potential of 1672.99%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3398.25%. Given that Theriva Biologics, Inc. has higher upside potential than Acurx Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Acurx Pharmaceuticals, Inc..

Acurx Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Acurx Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Acurx Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Acurx Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Acurx Pharmaceuticals, Inc.'s net income of -$2M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Acurx Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Acurx Pharmaceuticals, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.